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Abstract 
Background 
Many patients with psoriasis have undiagnosed psoriatic arthritis. Low specificity is found 
with many PsA screening tools. A new instrument, the CONTEST questionnaire, was 
developed utilising the most discriminative items from existing instruments. 
Objective 
The aim of this study was to compare the CONTEST and PEST screening tools. 
Methods 
People attending secondary care clinics with psoriasis, but not PsA, completed the 
questionnaires, were assessed for function and quality of life, and had a physical 
examination. Patients thought to have PsA were compared to those without. The 
performance of CONTEST and PEST were compared using area under the receiver operating 
curve (AUC), and sensitivity and specificity at the previously published cut-offs. 
Results  
451 dermatology patients were approached, 35% were reviewed, and 27 (17%, 95% CI 12.3 
 ? 21.7) had unidentified psoriatic arthritis. The sensitivity and specificity (95% CI) of PEST 
were 0.60 (0.42  ? 0.78)/0.76 (0.69  ? 0.83) and for CONTEST 0.53 (0.34  ? 0.72)/0.71 (0.63  ? 
0.79). The confidence limits for the AUC overlapped (AUC for PEST 0.72 (0.61  ? 0.84), for 
CONTEST 0.66 (0.54  ? 0.77).  
Conclusions 
PEST and CONTEST questionnaires performed equally well, with no superiority of the new 
CONTEST tool.   
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Introduction 
Background/rationale 
Psoriatic arthritis (PsA) manifests clinically in several ways including arthritis, enthesitis, 
dactylitis, axial disease and skin/nail involvement.  The majority of people with this 
condition have pre-existing psoriasis(1). A period of preclinical disease may occur, as well as 
cases of established disease going unidentified for some time(2). The reason why cases of 
established PsA remain unidentified is not clear, but one possible cause is the lack of 
musculoskeletal expertise in primary care and in dermatology clinics. A simple method of 
screening for PsA in people with psoriasis has the potential to prevent unnecessary suffering 
and enable earlier treatment of this potentially disabling disease. Recent consensus 
guidelines for managing psoriasis published by SIGN (The Scottish Intercollegiate Guidelines 
Network )(3) and NICE (https://www.nice.org.uk/guidance/cg153 - accessed 14th Oct 2017) 
recommend using questionnaires to screen for PsA. 
 Several patient completed instruments are currently available for screening PsA, including 
the Psoriatic Arthritis Screening Evaluation (PASE(4)), the Toronto Psoriatic Arthritis Screen 
(ToPAS(5)), the Psoriasis Epidemiology Screening Tool (PEST(6)), and the Early Psoriatic 
Arthritis Screening Questionnaire (EARP(7)). A recent comparison of three of these (PASE, 
ToPAS and PEST) in a secondary care setting determined that they all had a good probability 
of detecting PsA (sensitivity~80%), but had poor specificity (~35%)(8).The PEST questionnaire 
had the highest area under the curve for identifying PsA(8), but is criticised for its simplicity, 
in particular for missing axial forms of PsA(9). Further analysis of the results of the above 
study has identified the most discriminative questions from each of the three 
questionnaires, including questions about the back and neck, and these items have been 
combined to create a new single 8 item screening questionnaire (CONTEST). The aim of this 
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study was to evaluate the CONTEST screening questionnaire in a secondary care 
dermatology clinic using the PEST tool as the reference instrument. 
Materials and Methods 
Study Design 
This was an observational, cross sectional study of patients attending dermatology clinics in 
4 UK centres. Full ethical approval and informed consent were obtained. 
Setting & Participants 
Dermatology patients aged 18 and over with a confirmed diagnosis of psoriasis and no 
diagnosis of inflammatory joint disease from 4 UK secondary care sites (Leeds, Bradford, 
Salford and Bath) were approached between November 2013 and March 2017. Potential 
participants were invited to participate during their routine dermatology appointment, by 
letter from their current dermatologist, or at a routine phototherapy appointment. Those 
approached were given an invitation letter and detailed information sheet with local study 
contact details. Those who accepted or were posted study information were contacted no 
less than 1 week later to determine their interest to participate, and a single assessment 
visit scheduled, where written informed consent was obtained. 
Data & Variables 
At the assessment visit participants were asked to complete 2 quality of life and one 
functional ability questionnaires (Psoriatic arthritis quality of life questionnaire (PsAQoL), 
Dermatology Life Quality Index (DLQI), and Health Assessment Questionnaire, (HAQ), and 
the PEST and CONTEST questionnaires. Following completion, all participants were assessed 
by both a dermatologist (or dermatology research nurse) and a rheumatologist. Psoriasis 
type and symptoms were recorded, as well as demographic data and current psoriasis 
medication. Six clinical assessments were used to record skin and joint disease activity: 
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x The Psoriasis Area and Severity Index (PASI) 
x The modified Nail Psoriasis Severity Index (mNAPSI) 
x The Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis count 
x The Leeds Enthesitis Index (LEI) enthesitis count 
x The 20-digit tender dactylitis count 
x the 68 tender and 66 swollen joint count 
Spinal mobility measures were recorded for those with inflammatory axial symptoms. CRP 
and ESR were also recorded if available from patient records. The rheumatologist was asked 
to classify patients as PsA, no MSD (musculoskeletal disease) or other MSD. The CASPAR 
criteria were also assessed.  
Study Sample Size 
The sample size estimate was determined by the number of patients required to validate 
previously obtained figures for sensitivity and specificity of the CONTEST questionnaire. The 
sensitivity and specificity of the CONTEST questionnaire in development were 0.82 and 0.52 
respectively.  Assuming a prevalence of PsA of 20%, and to confirm sensitivity and specificity 
with a minimum accuracy of 10% and a confidence level of 95%, the minimum number 
required for the total sample size was 246. 
Statistical methods 
Data from patient completed quality of life and functional ability questionnaires were 
summed and/or scored according to each instruments protocol and treated as interval data 
after testing for normal distribution. As data from clinical measurements consisted of 
counts, this data was also treated as interval data and summed according to protocol. 
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Analysis of the sensitivity and specificity of each the questionnaire was done using receiver 
operator characteristic (ROC) curves, allowing for the assessment of different cut-points for 
the new CONTEST questionnaires.   
Results 
Participants 
Four hundred and fifty one dermatology patients were approached across the 4 
participating centres, with 43% (n=194) recruited from Leeds. Thirty five percent (n = 159) 
across all 4 centres consented and were assessed. Ninety five percent of participants were 
identified as North European. The mean age of psoriasis diagnosis was 29 years (95% C.I. 
26,31). There was no age or sex recruitment bias. 
Among those assessed, 27 (17%, 95% CI 12.3,21.7) were identified as having previously 
unidentified psoriatic arthritis (25 of these patients also fulfilled CASPAR criteria). The other 
participants were divided into those without any MSD (n=61) and those with other MSD 
(n=71) (Table 1). Those with PsA were older, more likely to be male, had a similar age of 
onset of psoriasis, and similar severity of skin and nail disease, although there was a trend 
towards more severe skin and nail disease in patients with PsA (Table 1). Further, those with 
PsA had worse functional ability, as measured by the HAQ, and quality of life, as measured 
by the PsAQoL and DLQI. Of the patients with PsA, the median tender and swollen joint 
counts were 3 (range 0  ? 41) and 0 (range 0  ? 4) respectively. Twelve (44%) had nail 
involvement. Median dactylitis count was 0 (range 0 - 2) and median enthesitis count was 0 
(range 0 - 20). There were no significant differences in psoriasis phenotype between the 
patients with PsA and the other groups (data not shown). The most frequent PsA sub-group 
in those with PsA was oligoarthritis (n = 16, 59%) followed by axial (n = 6, 22%), polyarthritis 
(n = 3, 11%) and distal inter-phalangeal joint only (n = 1, 4%). In terms of treatment 10 (37%) 
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of people diagnosed with PsA were taking biologics or systemic treatment (methotrexate or 
ciclosporin); the figures for no MSD were 17 (23%) and for other MSD 18 (25%). 
Incompleted questionnaires for the PEST and CONTEST instruments occurred in 14 cases 
(9%) for PEST, primarily question #4 concerning heel pain, and 30 cases (19%) for CONTEST, 
again primarily for a question concerning heel pain, but also for questions related to nail 
changes. Sensitivity and specificity for PEST were 0.60 (95% CI 0.42,0.78)/0.76 (95% CI 
0.69,0.83) and for CONTEST 0.53 (95% CI 0.34,0.72)/0.71 (0.63,0.79). The ROC curve analysis 
is presented in Table 2. The confidence limits for the AUC (area under the receiver operating 
curve) overlap between questionnaires so, although the PEST had the higher AUC, 
statistically there was no difference between them. 
The ability of the screening questionnaires to identify all the sub-groups of PsA is given in 
Table 3. The analysis is partly obscured by the number of missing questionnaire item 
responses but, nevertheless, from this table it is clear that the CONTEST does not have an 
obvious superiority in identifying the axial sub-group of PsA. 
Discussion 
The CONTEST questionnaire was developed using the best performing items from three 
other screening questionnaires in the hope that it would perform better than its originators. 
In development this was partly correct but the current study does not support this  ? 
statistically there was no difference between PEST and CONTEST in terms of ability to detect 
psoriatic arthritis in patients with psoriasis. 
The performance of both questionnaires is acceptable at the given cut-offs. It is, however, 
worth noting the discrepancy in sensitivity/specificity of these questionnaires across 
different studies. For example, the CONTEST study found lower specificity for all tested 
questionnaires(8) while maintaining acceptable sensitivities. On the other hand a study from 
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Dublin found the opposite  ? acceptable specificities with lower sensitivities(9). Some of these 
discrepancies will be due to subject selection (excluding people with any known rheumatic 
disease will improve specificity) and  the research environment (for example offering 
unselected subjects a chance to have a consultation with a rheumatologist may increase the 
proportion of those with all categories of musculoskeletal disease). Some of the differences 
may also be explained by those cases of PsA with axial disease which may favour one 
questionnaire over another.  
The relative simplicity of the PEST questionnaire has raised concerns that the tool is not able 
to detect pure axial forms of the disease. The CONTEST questionnaire includes items specific 
to back and neck pain, and so it was hoped it would better detect this subgroup. In this 
study this is not the case (see Table 3), although the numbers were small and imaging of the 
spine was not part of the study. The pure axial subgroup is uncommon (less than 10%); up to 
40% of cases of PsA have axial involvement with additional peripheral disease activity, and 
this may explain the success of the PEST in identifying axial forms of the disease. 
A proportion of the participants were already receiving systemic treatment for their 
psoriasis which may have suppressed the presentation of musculoskeletal symptoms. But a 
higher percentage of people diagnosed with PsA were already receiving systemic treatment 
would argue against this theory, and is consistent with a recent report from Italy which 
reported a large cohort of patients in whom PsA had developed while already taking biologic 
drugs(10). The higher prevalence of systemic drug use in the PsA group may represent a more 
severe form of psoriasis; traditionally the association between psoriasis severity and onset 
of PsA has been weak but there has been a recent report that the onset of PsA is related to 
the more severe forms of psoriasis(11).  
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The prevalence estimate of previously undiagnosed PsA is within the range encountered in 
other studies, but probably less than would be expected in a secondary care setting(2, 8, 12). 
The reasons for this are likely multifactorial. Firstly, other screening studies have previously 
been performed at two out of the three sites that participated in this study, and it is 
ƉŽƐƐŝďůĞƚŚĂƚƚŚĞ ?ƉŽŽů ?ŽĨƵŶƌĞĐŽŐŶŝƐĞĚWƐǁĂƐƌĞĚƵĐĞĚďǇƚŚĞƐĞƉƌĞǀŝŽƵƐĞĨĨŽƌƚƐ ?
Secondly, in the main participating site, a triage clinic for new psoriasis referrals was 
introduced towards the latter half of the current study  ? this is also likely to have impacted 
the prevalence of unrecognised PsA in this population. As with many such studies the results 
should be interpreted with caution for the above reasons and because only a minority of 
invitees agreed to take part.  
In addition to the aforementioned problem (heterogeneity across sites) a further limitation 
of this study was the failure to achieve the planned sample size of 246 participants. 
Therefore it is possible that this study was underpowered to validate the pre-existing 
performance of the CONTEST questionnaire. However, the sensitivity and specificity were 
different to those anticipated: the specificity exceeded that found in the original study and 
sensitivity was lower and, although the confidence intervals of the estimate were wide, they 
did not encompass the original estimate for sensitivity.  
In conclusion this study in a secondary care setting has shown equivalent performance of 
the PEST and CONTEST questionnaires, with no superiority of the more comprehensive 
CONTEST tool. PEST is a short and simple screening tool which should be used to assess the 
possibility of psoriatic arthritis in patients with psoriasis. A positive response requires 
further assessment of the musculoskeletal symptoms.  
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Figure 1: Screening for Arthritis in Psoriasis study flow diagram for participants 
 
Flow Diagram 
 
  Approached (n=451) 
Analysed (n=159) 
Excluded from analysis (n=0) 
No (n=292) 
Yes (n=27) 
Analysis 
Enrollment 
Consent/Assessed Yes (n=159) 
PsA No (n=132) 
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Table 1. Demographic and clinical characteristics of participants. 
 Psoriatic arthritis No MSD Other MSD+ Statistic P 
n 27 61 71   
Age, y 52.7 ± 12.0 43.5 ± 13.0 49.7 ± 15.1 5.4 0.006 
Duration 
psoriasis, y 
33.8 ± 17.3 28.2 ± 14.7 27.1 ± 17.2 1.5 ns 
Gender M/F 18/9 40/21 33/38 6.1* 0.05 
PASI 7.2 ± 8.7 6,3 ± 6.2 4.7 ± 4.9 2.0 ns 
mNAPSI 10.7 ± 16.6 5.3 ± 9.7 7.2 ± 10.8  2.6 0.08 
HAQ 0.52 ± 0.54 0.10 ± 0.30 0.30 ± 0.40 9.7 0.0001 
PsAQoL 7.0 ± 6.0 2.5 ± 4.2 5.6 ± 6.0 8.8 0.0001 
DLQI 8.4 ± 6.5 6.6 ± 6.9 6.4 ± 5.3 1.1 ns 
PEST A? 3 15/25 (60) 6/58 (10) 23/62 (37) 22.7* 0.0001 
CONTEST A? 4 10/19 (53) 8/54 (15) 24/56 (43) 13.9* 0.001 
 
MSD: musculoskeletal disease 
PASI: psoriasis area and severity index 
mNAPSI: modified nail psoriasis severity index 
HAQ: health assessment questionnaire  
PsAQoL: psoriatic arthritis quality of life  
DLQI: dermatology life quality index 
Statistic is F (analysis of variance) unless indicated with an asterix (chi squared test) 
+ osteoarthritis (n = 40); soft tissue disorder (n = 12); mechanical low back pain (n = 6); 
hypermobility syndrome (n = 4); injury (n = 3); gout (n = 2); fibromyalgia (n = 2); missing (n = 
2).  
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Table 2. Sensitivities and specificities of selected cut offs for the questionnaires (usually 
applied cut off in bold). Figures derived from the ROC curves. AUC: area under the ROC 
curve. Sens: sensitivity. Spec: specificity. 
 
  
Questionnaire    AUC 95% CI 
PEST Cut point Sens Spec 0.723 0.609  ? 0.836 
 2 0.80 0.49   
 3 0.60 0.76   
 4 0.40 0.88   
CONTEST    0.655 0.536  ? 0.774 
 3 0.63 0.54   
 4 0.53 0.71   
 5 0.32 0.80   
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Table 3. PsA sub-type and number of questions answered affirmatively in each of the 
questionnaires. 
The darker grey shading indicates that the score range in which the questionnaire would 
have deemed to be positive, given usual cut offs. 
  
Questionnaire  Number of questions answered positive  
PEST 0 1 2 3 4 5 Total 
        
Oligoarthritis 0 2 3 3 6 1 15 
Polyarthritis 0 0 0 1 1 1 3 
Axial 1 1 2 1 1 0 6 
DiP 1 0 0 0 0 0 1 
        
CONTEST 1 2 3 4 5 6  
        
Oligoarthritis 1 3 0 3 4 2 13 
Polyarthritis 0 0 0 0 0 0 0 
Axial 2 0 2 1 0 0 5 
DiP 0 1 0 0 0 0 1 
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